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a b s t r a c t
Canine mast cell tumours often express KIT mutations that result in constitutive activation
of the c-kit receptor and which are associated with more aggressive disease. The aim of
the current study was to determine whether small inhibitory RNA (SiRNA) molecules could
speciﬁcally target canine KIT mRNA for knock-down. Canine beta-2 microglobulin (B2M),
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and KIT sequences were cloned into
the psiCHECKTM-2 vector. SiRNA molecules, designed to target gene-speciﬁc sequences,
were co-transfected with plasmid DNA into Chinese hamster ovary (CHO) cells. Renilla and
ﬁreﬂy luciferase activity was measured using the Dual-GLO® Luciferase Assay (Promega).
Using this reporter system, canine housekeeping gene-speciﬁc SiRNA molecules demon-
strated knockdown of their targets (72.0% knockdown for B2M and 94.5% knockdown for
GAPDH). An SiRNA molecule targeting exon 2 of canine KIT successfully knocked-down
reporter gene expression of a KIT26–407 construct (90.8% knockdown). An SiRNA molecule
targeting a 48 base-pair in-tandemduplicationmutation in KIT exon 11 selectively knocked
down expression of the KIT1569–1966mutant construct (93.1% knockdown) but had no effect
on the KIT1569–1918wild-type construct. The results show that RNA interference can be used to
inhibit canine KIT mRNA expression and has the potential to selectively target the mutant
version of KIT that is expressed by some malignant mast cells.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
Mast cell tumours (MCT) are the most common skin
malignancy in dogs and are thought to arise from neoplas-
tic transformation of tissuemast cells (reviewedbyDobson
and Scase, 2007; Welle et al., 2008). In order to become
Abbreviations: CHO, Chinese hamster ovary; SiRNA, small inhibitory
RNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; B2M, beta-
2 microglobulin; TRAIL, TNF related apoptosis-inducing ligand; XIAP, X-
linked inhibitor of apoptosis protein.
∗ Corresponding author. Tel.: +44 01707 666801;
fax: +44 01707 652090.
E-mail address: bcatchpole@rvc.ac.uk (B. Catchpole).
malignant, mast cells must be able to resist those mech-
anisms associated with programmed cell death, to allow
survival and proliferation. Developing a greater under-
standing of how such cells prevent apoptosis might enable
us to designmore rational treatment strategies for this type
of cancer.
Mast cell viability in healthy tissues is regulated by stem
cell factor (SCF) via its action on the KIT receptor (CD117),
which has tyrosine kinase activity (Qiu et al., 1988). SCF
binding to KIT is thought to provide survival signals,
by inhibiting apoptosis through modulation of apoptosis-
regulatory proteins (Galli and Kitamura, 1987; Taylor and
Metcalfe, 2000). In human mast cells, overexpression of
Bcl-2 or Bcl-xL, protects against programmed cell death
0165-2427/$ – see front matter © 2011 Elsevier B.V. All rights reserved.
doi:10.1016/j.vetimm.2011.02.006
152 R.C. Elders et al. / Veterinary Immunology and Immunopathology 141 (2011) 151–156
and is thought to contribute to oncogenesis (Cerveró et al.,
1999; Hartmann et al., 2003). Mutations in the KIT gene
are found in 15–50% of canine MCT, which typically consist
of in-tandem duplications, located in or around exon 11
(London et al., 1999; Ma et al., 1999; Downing et al., 2002;
Webster et al., 2006). When expressed, such mutations
often result in autophosphorylation of the intracellular
kinase domain of the receptor protein, leading to con-
stitutive activation, even in the absence of SCF (London
et al., 1999; Ma et al., 1999; Pryer et al., 2003). Thus,
canine mast cells seem to be capable of developing inde-
pendence from growth/survival signals, one of the key
features ofmalignancy (HanahanandWeinberg, 2000). The
C2mastocytoma cell line,which is commonly used to study
canine malignant mast cell biology in vitro, expresses a 48
base-pair in-tandem duplication (London et al., 1999; Ma
et al., 1999), although the precise location, nature and size
of mutations can vary between different MCTs (Downing
et al., 2002; Webster et al., 2006; Letard et al., 2008).
KIT activating mutations have been shown to be asso-
ciated with MCT of a more aggressive phenotype, which
is likely due to increased proliferation and resistance
to apoptosis (Gleixner et al., 2007; Letard et al., 2008).
This has led to several investigations into the therapeutic
potential of receptor tyrosine kinase inhibitors (RTKi),
designed to target this molecule. There are currently
two drugs (masitinib, Masivet®, AB Science; toceranib,
Palladia®, Pﬁzer) that have recently been licensed for
canine MCT. However, these compounds are not speciﬁc
for KIT and also inhibit other receptor tyrosine kinases,
such as platelet-derived growth factor receptor (PDGFR)
and vascular growth factor receptor (VEGFR2) (Rubin
et al., 2001; Hayes and Thor, 2002; Humbert et al., 2009;
London et al., 2009). Although the lack of speciﬁcity might
enhance the anti-cancer efﬁcacy of these drugs, this could
also increase the risk of adverse effects in the patient.
In addition, these RTKi will not have speciﬁc effects on
malignant mast cells, as they will also inhibit wild-type
KIT, expressed by tissue mast cells and other cell types
including haematopoietic stem cells and melanocytes
(Galli et al., 1994; Linnekin et al., 1997) Molecular tech-
niques, such as gene silencing by RNA interference, offer an
alternative, potentially more speciﬁc method for targeting
mutant KIT that might be applicable for canine MCT, as
well as for human gastrointestinal stromal cell tumours
that commonly express similar KIT mutations (Lasota
et al., 2003; Steigen et al., 2007; Du et al., 2008).
RNA interference can be used to target speciﬁc mRNA
for degradation (Spee et al., 2006; Tsuchiya et al., 2006;
Watanabe et al., 2009). Thus, gene expression can be
selectively silenced, preventing production of the encoded
protein, which allows experiments to be designed to deter-
mine the role of that speciﬁc gene product on cellular
function. The aim of the current study was to determine
whether small inhibitory RNA (SiRNA) molecules could be
designed to knock-down canine KIT expression. In par-
ticular we aimed to design novel SiRNA molecules that
speciﬁcally targeted the mutant KIT expressed by C2 cells
that would spare expression of the wild-type receptor.
Chemical transfection of C2 cells proved to be problem-
atic, despite repeated attempts using various transfection
reagents and protocols. Therefore, to allow investigation
of the activity of the siRNA molecules to speciﬁcally inter-
fere with their target canine mRNA, we investigated use of
a reporter gene assay to assess the ability of canine KIT-
speciﬁc SiRNA molecules to knock-down their target.
2. Materials and methods
2.1. Plasmid DNA constructs and SiRNA molecules
Partial coding regions for selected canine genes were
ampliﬁed by PCR from cDNA prepared from the C2
canine mastocytoma cell line (a generous gift from Dr
B. Helm, University of Shefﬁeld; originally generated by
Prof. W. Gold, University of California) (Lazarus et al.,
1986), which expresses both wild-type KIT as well as a
KIT exon 11 mutation (Fig. 1). PCR products represent-
ing canine glyceraldehyde-3-phosphate dehydrogenase;
GAPDH520–971 (sense primer: ACCACCGTCCATGCCAT-
CAC; antisense primer: TCCACCACCCGGTTGCTGTA;
452bp amplicon), beta-2 microglobulin; B2M47–379
(sense primer: TCCTCATCCTCCTCGCT; antisense primer:
GTCAGTTGTCTCGGTCCCAC; 333bp amplicon), KIT26–407
(KIT1: sense primer: ATTTTCTCTGCGTCCTGCTC; antisense
primer: ACCAGCGTATCATTGCCTTC; 382bp amplicon),
KIT1569–1920wild-type and KIT1569–1968mutant (KIT2: sense
primer: CCTGTTCACACCTTTGCTGA; antisense primer
TAGGGCTTCTCGTTCGGTTA; 352bp amplicon for wild-
type, 400bp amplicon for mutant) were initially cloned
into the pSC-A vector (Stratagene, La Jolla, CA). Plasmid
DNA from recombinant clones was sequenced to conﬁrm
the integrity of the inserts, which were then sub-cloned
into the psiCHECKTM-2 vector (Promega, Southampton,
UK). This vector contains both ﬁreﬂy and renilla luciferase
reporter genes under the control of separate promoters.
Each canine gene-speciﬁc sequence was inserted down-
stream of the renilla luciferase element using NotI and
XhoI restriction sites, which will result in expression of the
target sequence in the 3′UTRof the renilla luciferasemRNA.
Following transfection, any changes in renilla luciferase
activity, which might result from siRNA binding and
knockdown of the fusion mRNA, can thus be normalized
against ﬁreﬂy luciferase activity. Plasmid DNA was then
extracted from recombinant E.coli using the GenEluteTM
Endotoxin-free Miniprep Kit (Sigma, Poole, UK) in prepa-
ration for transfection studies. The SiRNA molecules used
in the study are shown in Table 1. In addition, a scrambled
SiRNA molecule (AllStars Negative Control SiRNA, Qiagen,
Crawley, UK) was used as a negative control.
2.2. Cell culture and transfections
Chinese hamster ovary (CHO) cells were maintained
in 75 cm2 ﬂasks of culture medium consisting of Minimal
Essential Medium (Sigma. Poole, UK) supplemented with
10mM Glutamax-1 (Invitrogen) 10% foetal bovine serum
(Serotec, Kidlington,UK) and25g/ml gentamicin (Sigma).
Cells for transfection studies were plated out in triplicate
wells in Corning 96 well clear bottom, white microtitre
plates (Sigma) at 1×104 cells in a 100l volume of cul-
ture medium lacking serum and antibiotics. Cells in each
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Fig. 1. The C2 cell line expresses both wild-type KIT and a KIT exon 11 mutant. (a) cDNA was prepared from C2 cells and used as the template for PCR
using primers spanning KIT exon 11. PCR products were separated by 2% agarose gel electrophoresis. Anticipated amplicon size =352bp for wild-type KIT
and 400bp for the mutant version, which contains a 48bp in-tandem duplication. MWt=200bp molecular weight marker. (b) Sequence of KIT mutation
in C2 cells. Partial genomic DNA sequence is shown with exon 11 highlighted. The 48bp mutation is shown in bold and the region targeted by the SiRNA
molecule is underlined.
wellwere transfectedwith 200ngplasmidDNAand5pmol
SiRNA using Lipofectamine 2000TM (Invitrogen) according
to the manufacturer’s instructions. Plates were incubated
for 4h then the complex-containing medium was replaced
with culture medium lacking antibiotics.
2.3. Luciferase assay
Twenty four hours after transfection, cells were assayed
for both ﬁreﬂy and renilla luciferase activity using the
Dual-GLO® Luciferase Assay System (Promega). Brieﬂy,
cells were lysed and the ﬁreﬂy luciferase substrate added
(50l per well Dual-GLO® Substrate/Buffer). After 15min,
luciferase activity was measured using a luminometer
(Spectramax M2, Molecular Devices). Next the renilla
luciferase substratewas added (50l perwell Stop &GLO®
Substrate/Buffer) and the luminescence measured after
a further 15min incubation. The renilla/ﬁreﬂy luciferase
ratio was calculated from the mean luminescence val-
ues of triplicate wells, after blanking against values from
untransfected cells. The percentage knockdown using test
SiRNA molecules was calculated compared to the control
scrambled SiRNA and data are shown as the mean of three
experimental replicates.
3. Results & discussion
3.1. Knock-down in expression of canine housekeeping
genes
Few studies have beenperformedusing SiRNA to specif-
ically knock-down canine gene expression. In terms of
studying the biology of canine malignant cells, siRNA
targeting apoptosis-modulator molecules including Bcl-2
(Watanabe et al., 2009), Bcl-xL (Tsuchiya et al., 2006) and
XIAP (Spee et al., 2006) have previously been undertaken in
Table 1
Plasmid DNA constructs and SiRNA molecules used in knock-down studies.
Target gene Plasmid DNA construct SiRNA molecule SiRNA target sequence SiRNA source
Renilla luciferase psiCHECK-2 Renilla tggcctttcactactcctacg Custom synthesized (Ambion)
GAPDH psiCHECK-2/GAPDH520–971 GAPDH#1exon8a ccactttgtcaagctcatt Custom synthesized (Ambion)
GAPDH psiCHECK-2/GAPDH520–971 GAPDH#2exon8b cgacatcaagaaggtagtg Custom synthesized (Ambion)
B2M psiCHECK-2/B2M47–379 B2M#1exon2a ctcccaatgagcaggatga Custom synthesized (Sigma)
B2M psiCHECK-2/B2M47–379 B2M#2exon2b ccgtgtaaagcatgttact Custom synthesized (Sigma)
KIT psiCHECK-2/KIT26–407 KITexon2 ggctcttctcaaccatctg Silencer® SiRNA 35 (Ambion)
KIT psiCHECK-2/KIT1569–1966mutant KITexon11mut agaacatacccaacacagc Custom synthesized (Ambion)
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canine cancer cell lines. In the current study, several SiRNA
moleculeswere initially assessed thatweredesigned to tar-
get canine housekeeping genes. Using a renilla luciferase
SiRNA molecule as a positive control, efﬁcient knock-
downof canineGAPDHwas demonstrated, although SiRNA
molecules targeting beta-2 microglobulin were less effec-
tive (Table 2). The increase in ﬁreﬂy luciferase activity
seen in CHO cells co-transfected with plasmid DNA with
scrambled siRNA, compared to those cells transfected with
plasmid DNA alone, might be explained by the greater
amount of transfection reagent used, leading to increased
transfectionefﬁciency.A further increase inﬁreﬂy lumines-
cence was seen in CHO cells co-transfected with targeted
siRNA compared to scrambled siRNA. This pattern of reac-
tivity might be explained if ﬁreﬂy and renilla luciferase
mRNA compete for translation. Thus, following successful
targeting of the renilla-fusion mRNA for destruction, this
could lead toenhancedﬁreﬂy luciferaseproteinexpression.
3.2. Knock-down in expression of canine KIT
To investigate the biological effect of KIT RNA inter-
ference, the C2 canine mastocytoma cell line was chosen
for in vitro studies. The mutation present in the KIT gene
expressed by C2 cells consists of a 48bp in-tandem dupli-
cation in exon 11. The C2 cells used in the current study
expressed both wild-type and mutant KIT mRNA (Fig. 1),
with the latter seeming to dominate. Since C2 cells are het-
erozygous for the mutation, it is possible that the mutant
allele is transcribed at a higher level, or that the mutant
transcript is more stable than the wild-type transcript.
Expression of wild-type KIT seems to be variable in C2 cells
with expression reportedly absent in cells used in some
(Ma et al., 1999) but not all previous studies (London et al.,
1999).
Since no KIT siRNA molecules had been validated for
the dog, several human KIT siRNAs that had been shown
to be effective (Lefevre et al., 2004; Li et al., 2007; Sikarwar
and Reddy, 2008)were assessed for sequence identitywith
the canine KIT sequence. A commercially available and val-
idated KIT SiRNA molecule (Silencer® SiRNA 35, Ambion),
which demonstrated complete sequence identity between
human and canine target sequences, was selected which
demonstrated >90% knock-down efﬁciency (Table 2). The
KITexon2 SiRNA molecule is not speciﬁc to the mutant KIT
sequence and would be expected to knock-down both
wild-type and mutant KIT mRNAs. The presence of the
mutation generates a unique sequence at the 5′ junction
of the insertion (Fig. 1). Therefore, a novel canine KIT
SiRNA molecule was designed, that targeted this region
to determine whether it might be possible to speciﬁcally
knock-down the mutant, while sparing expression of wild-
type KIT. When tested against constructs containing either
the wild-type sequence or the mutant version, this SiRNA
molecule demonstrated efﬁcient knock-down when using
theKIT2mutant construct (mean93.1%knock-down) but had
little effect on the KIT2wild-type construct (mean −2.98%
knock-down) (Fig. 2).
Due to the relatively large size of the KIT coding
sequence (almost 3kB) and the problems associated with
cloning this in entirety, we opted to clone only the speciﬁc Ta
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Fig. 2. Knockdown efﬁciency of an SiRNA molecule that targets the C2 KIT mutation. Recombinant psiCHECK-2 plasmid DNA was generated containing
either the 5′ region of canine KIT (KIT1) or the region containing exon 11 (KIT2) of either the wild-type or mutant version of the gene. Triplicate wells of
CHO cells were transfected with recombinant psiCHECK-2 plasmid DNA and selected wells were co-transfected with scrambled siRNA (negative control),
renilla SiRNA (positive control) or siRNA targeted to KIT (either exon 2 or the in-tandem duplication mutation within exon 11). Both ﬁreﬂy and renilla
luminescence were measured after 24h incubation. The renilla/ﬁreﬂy luciferase ratio are shown which represents the knock-down capability of the SiRNA
molecule on the target mRNA. A representative experiment is shown of three replicates.
regions of the KIT coding sequence targeted by the SiRNA
molecules selected/designed. This strategy has its disad-
vantages, since the secondary structure of the native KIT
mRNA is lost,whichmight inﬂuence the efﬁciency of SiRNA
silencing. This also precludes assessment of the effect of
SiRNA on KIT protein expression, although the reporter
gene assay is based on evaluation of luciferase activ-
ity, rather than mRNA expression. Both ﬁreﬂy and renilla
luciferase activity were consistently lower when using the
psiCHECK-2 construct containing mutant KIT, compared
to the native vector or vector containing wild-type KIT
sequences. Endotoxin contamination of the plasmid DNA
was considered, but a new batch of plasmid DNA demon-
strated the same response. Theexplanation for this reduced
efﬁciency of luciferase activity with this particular con-
struct remains unclear. Despite this, the KITexon11mut SiRNA
molecule demonstrated speciﬁcity of activity against the
mutant KIT construct, without affecting expression from
the construct containing the equivalent wild-type KIT
sequence.
In the current study, we have attempted to validate
several canine gene-speciﬁc SiRNA molecules. These can
now be assessed in canine cell lines and it is anticipated
that alternative delivery systems (e.g. electroporation, viral
vectors) will allow evaluation of these molecules in the
C2 cell line. We have shown as “proof-of-concept” that
SiRNA molecules can be designed to speciﬁcally target KIT
mutations, although the heterogeneity of mutations seen
in canine MCT means that it is unlikely that a single SiRNA
molecule could be designed that would be effective in all
cases.
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